Trial Profile

Open Label Trial of Ranolazine in Myotonia Congenita, Paramyotonia Congenita, & Myotonic Dystrophy Type 1

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Mar 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ranolazine (Primary)
Indications Myotonia; Myotonic disorders; Myotonic dystrophy
Focus Therapeutic Use

Most Recent Events

09 Feb 2018 Status changed from recruiting to completed.
14 Jul 2017 Results (n=13) assessing the effect of ranolazine on signs and symptoms of muscle stiffness and myotonia in patients with myotonia congenita, published in the Neurology Journal.
26 Jan 2017 Planned End Date changed from 1 May 2017 to 1 Dec 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com